



CODEN [USA]: IAJPBB

ISSN: 2349-7750

## INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES

Available online at: <http://www.iajps.com>

Research Article

### A COMPARISON OF PERI-PROCEDURE NON-Q WAVE FREQUENCIES OF MYOCARDIAL INFARCTION AMONG PATIENTS TREATED WITH AND WITHOUT HIGH DOSE OF ATORVASTATIN

<sup>1</sup>Dr. Asad Ali, <sup>2</sup>Dr. Abdul Rehman, <sup>3</sup>Dr. Shahzad Amin Virk

<sup>1</sup>Medical Officer, Sheikh Zayad Medical College Rahim Yar Khan, <sup>2</sup>MO, DG Khan Medical College, <sup>3</sup>MO, SZMC Rahim Yar Khan.

Article Received: March 2019

Accepted: April 2019

Published: May 2019

**Abstract:**

**Background:** An important disorder is the periprocedural myocardial infarction. In recent studies, its greater intake has been greatly studied.

**Objective:** The main purpose of the study is to compare the speed of peri-procedural non-Q-wave myocardial infarction between the sufferers who gained and not gained greater quantity atorvastatin prior to percutaneous coronary interference.

**Material and methods:** We carried out this research at Services Hospital, Lahore from October 2017 to July 2018. The patients having irregular angina on continual blemish healing enduring PCI were randomized to atorvastatin greater dosage bolus group 1 or group 2 no atorvastatin.

**Results:** The average age of the patients present in group 1 is 53 years. The average age of the group 2 was 55 years. In group 1 most of the patients were women. In group 2 majorities are of men. In both, the groups 33% and 37% of patients were suffering from diabetes mellitus in group 1 and group 2 respectively. Moreover, in both the group's similar numbers of hypertensive and smokers were also found. In group 1 periprocedural was also found in 5.4% of patients. While periprocedural was found 17% in group 2.

**Conclusion:** From the consequences of the study it has been summarized that preloading with greater quantity atorvastatin bolus prior to PCI lessens peri-procedural MI in patients on unending statin treatment undergoing PCI.

**Keywords:** Periprocedural myocardial infarction, High dose atorvastatin, PCI.

**Corresponding author:****Dr. Asad Ali,**

Medical Officer, Sheikh Zayad Medical College Rahim Yar Khan.

QR code



Please cite this article in press Asad Ali et al., A Comparison of Peri-Procedure Non-Q Wave Frequencies of Myocardial Infarction among Patients Treated with and without High Dose of Atorvastatin., Indo Am. J. P. Sci, 2019; 06(05).

**INTRODUCTION:**

Increase of cardiac biomarker has been expressed to present in 5 to 40% patients after triumphant PCI [1]. The more chances of succeeding cardiac actions by creatine kinase or increased cardiac troponin even placid harm of myocardium. Many methods were discovered to resolve this problem [2, 3]. Damage in the myocardium during PCI and successive myocardial actions can be minimized by an inhibitor. The name of the inhibitor was Hydroxyl-3 methylglutaryl coenzyme A reductase [4]. Now a day's drug-eluting stent has been greatly used to give full exposure of coronary lacerations. Restenosis can be saved by a longer stent. So in the presence of stenting more myocardial damage will result [5, 6]. Statin treatment can be widely used for the cure of medical patients. After a little time of pretreatment with atorvastatin in statin-naïve patients with acute syndrome undergoing PCI was found to lessen the peri-procedural myocardial infarction.

The main purpose of the experiment was to analyze the difference between the speed of periprocedural non-Q-wave myocardial infarction of patients obtaining a high amount or not obtaining.

**MATERIAL AND METHODS:**

We carried out this research at Services Hospital, Lahore from October 2017 to July 2018. Patients were transferred for acute statin treatment. Total of 222 patients were added in the study. Patients were classified into two groups group 1 and group 2. Variations in ST identified the procedural non Q wave. The main reason for the infections was hypertension and smoking. The data were analyzed using SPSS.

**RESULTS:**

The division of study factors and danger features are expressed in tabular data. The average age of the patients in group A was 53 year. While in group B the average age limit was 55 years. In group 1 most of the strength of the patients were of women about 88%. The majority was of males in group B. Males were about 92% in group B. In both, the groups 33% and 37% of patients were found to be affected by diabetes. Tabular data also describes the comparison of causes of disorder like smoking and hypertension were described. The number of periprocedural MI was found 6 in group 1 and 17 in group 2.

**Table – I:** Study variables in both groups

Variable	Group-1	Group-2
Male	14	92
Female	97	19
Diabetes	37	41
Hypertension	42	42
Smoking	35	34
1 vessel stent	92	91
2 vessel stents	16	18
3 vessel stents	03	02






Table – II: Peri-procedural MI in study population

Atrovastatin 80mg	Peri-procedural MI		Total
	No	Yes	
Not given	94	17	111
Given	105	06	111



**Table – III:** Risk factors distribution among patients of peri-procedural MI in both groups

Variables	Group 1	Group 2
Mean age	53.66	55.88
Male	05	14
Diabetes	01	02
Hypertension	02	06
Smoking	03	09
1 vessel stent	03	09
2 vessel stent	03	07
3 vessel stent	0	01

**DISCUSSION:**

It was shown in our study that one greater quantity atorvastatin bolus prior PCI in irregular angina patients specifically decreased peri-procedural MI subsequent to PCR. Patients were primarily on atorvastatin in the recent study. Prior to PCI, a bolus of 80 mg was taken by every patient. The study was irregular. PCI methods were carried out on each patient.

Many irregular experiments have expressed that stains have advantageous impressions on the chances of long phrase cardiovascular procedures in matters with hypercholesterolemia disorder and in patients who undergo coronary intercession. ARMYDA in the first irregular experiment that was described. Liberation of all indicators of myocardial harm after coronary intercession was decreased by atorvastatin. Without considering the level of cholesterol patients were underwent atorvastatin therapy. The therapy

was done before 7 days of coronary intercession. The study utilizes a specific amount of statin for a brief time duration in an irregular manner.

Another irregular experiment was ARMYDA-ACS. It was shown that chances of cardiac actions in patients with sensitive coronary disorder underwent early PCI can be decreased petite phrase pretreatment with atorvastatin. This advantage can be specifically moved by the lessening of periprocedural MI [8]. ARMYDA-ACS experiment was formulated by ARMYDA. This was designed to detect either a sensitive weighting with elevated dose atorvastatin treated with PCI [8].

Atorvastatin boluses were given to the patients previously underwent with statin therapy in the recent experiment. This was the same as the utilization of atorvastatin in ARMYDA-Recapture examination [9]. Two amounts of the atorvastatin were given to

the patients in case of ARMYDA-Receptor experiment. Two doses of 40 mg were given to the patients in this case. In the recent experiment, a single dose of the atorvastatin of about 80mg was given to the patients. This reduces the second bolus. Patients having constant angina were added in the ARMYDA-ACS. However, in ARMYDA-Recapture and ARMYDA-ACS patients of unbalanced angina and NSTEMI were added.

Periprocedural MI by creatine kinase MB identification was identified after coronary intercession in 5% of patients in the statin group and 18% of those in the placebo group in the ARMYDA trial. An important decrease in the chances of periprocedural MI according to the measurements and observations made by using ARMYDA-ACS. To stay away from 1 case of periprocedural MI about 10 patients should be cured. Fewer chances of postprocedural creatine kinase-myocardial posse were expressed by ARMYDA-Recapture. And out of the upper border of regular in the atorvastatin arm versus placebo altitude was found in upper limit [7 – 9].

probable method of atorvastatin cardioprotection has been identified in the ARMYDA-ACS. It showed that mechanical fortification in the atorvastatin arm was paralleled by a decrease in PCI tempted endothelial inauguration [10]. This was shown by intercellular cell deviation particle 1 and E collection point at 24 hours subsequent to intercession. Details include atorvastatin tempted early amplification of endothelial progenitors cells, with the assistant method of stroke. This is according to the animal details. This shows decreased infarct size when sensitive statin shipment is given prior ischemia or prior to reperfusion fascinatingly. However in an animal study, this secure of cardio may diminish with the passage of time. It can be again amassed with a sensitive high amount of atorvastatin undertaken by patient spontaneously prior to ischemic. The impending medical resemblance was found in this mechanism.

The achievement of again the impressions which have baton off with the passage of time is the main advantage obtained by atorvastatin reentrance in our experiment because of atorvastatin bouls effect. Although pathophysiological details for atorvastatin loading is advantageous in statin naïve patients. The advantageous effects of atorvastatin are the requirement of statin interceded plaque balancing consequence in ACS patients “infiltrate” plaque imbalance with enhanced or “defiant” plaque swelling etc. The detail about the spontaneous

reactions of anti provocative, antithrombotic possessions of atorvastatin was described [14, 15]. It has been noticed that enhanced plaque swelling cell compactness with higher restricted construction of provocative lymphocytes was present in ACS patients. They also contain less anti provocative peacekeepers. Although patients were found to contain some level of myocardial defence during PCI prior to statin therapy. In addition, a dose linked platelet inhibitory or anti inflammatory sound effects of atorvastatin may have be effective [15, 16]. Due to the greater quantity of atorvastatin reduction was noticed in platelet commencement and plasma chemokine levels [17]. In the locale of PCI thrombosis and inflammation are related in the pathogenesis of tangential myonecrosis. This was specifically recorded in ACS patients. This concept supports the usage of greater amount of drugs in our experimentation. Our experiment is similar to other studies. It is more closely associated with ARMYDA succession.

#### CONCLUSION:

It has been noticed from the reports of the study that preloading with high amount of 80 mg atorvastatin bolus prior to PCI decreased peri-procedural MI in patients on constant statin therapy enduring PCI.

#### REFERENCES:

1. Vasa M, Fichtlscherer S, Adler K. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable CAD. *Circ* 2001; 103: 2885-90.
2. Jones SP, Trocha SD, Lefer DJ. Pretreatment with simvastatin attenuates myocardial dysfunction after ischemia and chronic reperfusion. *Arter Thromb VascBiol* 2001; 21: 2059-64.
3. Bell RM, Yellon DM. Atorvastatin administrated at the onset of reperfusion. *J Am Coll Cardiol* 2003; 41: 508-15.
4. Schulz R. Pleiotropic effects of statin: acutely good, but chronically bad? J, Larman A, Baumgart D. Procedural statin medication reduces the extent of peri-procedural non-Q-Wave MI. *Circ* 2002; 106: 2180-3.
5. Patti G, Pasceri V, Colonna G, Miglionico M, Fischetti. Pretreatment improves outcome in patients with acute coronary syndrome undergoing early PCI. *J Am Coll Cardiol* 2007; 49: 1272-8.
6. Pasceri V, Patti G, Nusca A. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention. *Circ* 2004; 110: 674-8.
7. Arrays PW, Defeyter P, Macaya C. Fluvastatin

- for prevention of cardiac events followings first PCI. JAMA 2002; 287: 3215-22.1.
8. Brigouri C. Impact of a single high loading dose of atorvastatin on periprocedural MI. Available at: [www.assetscardio-vascular.com](http://www.assetscardio-vascular.com). NAPLESH Briguori. Ppt. Accessed March 2009.
  9. Sciascio G, Patti G, Pasceri V, Gaspardone A, Colonna G, Montinaro A. Efficiency of atorvastatin reload in patients on chronic statin therapy undergoing PCI. J Am Coll Cardiol 2009; 54: 558-65.
  10. Patti G, Chello M, Pasceri V. Protection from procedural myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after PCI. J Am Coll Cardiol 2006; 48: 1560-8.
  11. Herrmann J, Lerman A, Baumgart D. Procedural statin medication reduces the extent of periprocedural non-Q-Wave MI. Circ 2002; 106: 2180-3.
  12. Sanguini V, Pignatelli P, Lenti L. Short term treatment with atorvastatin reduces platelet CD 40 ligand and thrombin generation in hypercholesterolemia patients. Circ 2005; 111: 412-9.
  13. Fuchs SH, Grunberg LU, Single et al. Prognostic value of Cardiac troponin I relevation following PCI in high-risk patients with ACS. Am J Cardiol 2001; 88:129-133.
  14. Saucedo JF, Mehran R, Danger G, Hong MK, Lanskyu AKent KM et al. long term clinical events following creatine kinase-myocardial band isoenzymes elevation after successful coronary stenting. J Am Coll Cardiol 2000; 35: 1134-41.
  15. Wang FW, Osman A, Otero J, Stouffer GA, Waxman S, Afzal A et al. Distal myocardial protection during PCI with an intracoronary beta blocker. Circ 2003; 107: 2914-9.
  16. Briguori C, Colombo A, Airoidi F, Violante A, Focaccio A, Blasterieri P et al. Statin administration before PCI: Impast on periprocedural MI. Eur Heart J 2004; 25: 1822-8.
  17. Patti G, Nusca A, Pasceri V. Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long term outcome in patients undergoing PCI. Jam Cardiol 2008; 101: 279-85.